Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: Results from the ANRS-AERLI intervention study

Addiction

Volumn 111, Issue 1, 2016, Pages 94-106

  Roux, Perrine ^a,b,c   Le Gall, Jean Marie ^d   Debrus, Marie ^e   Protopopescu, Camélia ^a,b,c   Ndiaye, Khadim ^a,b,c   Demoulin, Baptiste ^a,b,c   Lions, Caroline ^a,b,c   Haas, Aurelie ^d   Mora, Marion ^a,b,c   Spire, Bruno ^a,b,c,d   Suzan Monti, Marie ^a,b,c,d   Carrieri, Maria Patrizia ^a,b,c  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d AIDES   (France)

^e République Démocratique du Congo   (France)

Author keywords

Education; HCV; HIV; Injecting drug user; Intervention; Local complications

Indexed keywords

ADULT; CLINICAL TRIAL; CLUSTER ANALYSIS; COMMUNICABLE DISEASE; COMMUNITY CARE; COMPLICATION; FEMALE; FRANCE; HARM REDUCTION; HEALTH EDUCATION; HEPATITIS C; HIGH RISK BEHAVIOR; HIV INFECTIONS; HUMAN; MALE; MULTICENTER STUDY; PROCEDURES; PROGRAM EVALUATION; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

ADULT; CLUSTER ANALYSIS; COMMUNICABLE DISEASES; COMMUNITY HEALTH SERVICES; FEMALE; FRANCE; HARM REDUCTION; HEALTH EDUCATION; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PROGRAM EVALUATION; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84945570210     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13089     Document Type: Article

References (46)

1. Aspinall E. J., Nambiar D., Goldberg D. J., Hickman M., Weir A., Van Velzen E. et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol 2014; 43: 235-48.
2. Gowing L., Farrell M. F., Bornemann R., Sullivan L. E., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; 10: CD004145. doi: 10.1002/14651858.CD004145.pub4. Review.
3. Emmanuelli J., Desenclos J. C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 2005; 100: 1690-700.
4. Jauffret-Roustide M., Pillonel J., Weill-Barillet L., Léon L., Strat Y. L., Brunet S. et al. Estimation of HIV and hepatitis C prevalence among drug users in France - First results from the ANRS-Coquelicot 2011 Survey. Bull Epidemiol Hebd (Paris) 2013; 39-40: 504-9.
5. Blome M. A., Bjorkman P., Flamholc L., Jacobsson H., Molnegren V., Widell A. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program. J Viral Hepatol 2010; 18: 831-9.
6. Somaini B., Wang J., Perozo M., Kuhn F., Meili D., Grob P. et al. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care 2000; 12: 449-60.
7. Alter M. J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
8. Palmateer N., Hutchinson S., McAllister G., Munro A., Cameron S., Goldberg D. et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepatol 2014; 21: 25-32.
9. Nelson P. K., Mathers B. M., Cowie B., Hagan H., Des Jarlais D., Horyniak D. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
10. Pieper B., Kirsner R. S., Templin T. N., Birk T. J. Injection drug use: an understudied cause of venous disease. Arch Dermatol 2007; 143: 1305-9.
11. Lloyd-Smith E., Wood E., Zhang R., Tyndall M. W., Sheps S., Montaner J. S. et al. Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health 2010; 10: 327.
12. Kerr T., Wood E., Grafstein E., Ishida T., Shannon K., Lai C. et al. High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) 2005; 27: 62-6.
13. Cherubin C. E., Sapira J. D. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med 1993; 119: 1017-28.
14. Degenhardt L., Gilmour S., Shand F., Bruno R., Campbell G., Mattick R. P. et al. Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. Drug Alcohol Rev 2013; 32: 468-74.
15. Valenciano M., Emmanuelli J., Lert F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction 2001; 96: 597-606.
16. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004; 150: 1-10.
17. Dwyer R., Topp L., Maher L., Power R., Hellard M., Walsh N. et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend 2009; 100: 9-16.
18. Marshall B. D., Milloy M. J., Wood E., Montaner J. S., Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011; 377: 1429-37.
19. Rachlis B., Lloyd-Smith E., Small W., Tobin D., Stone D., Li K. et al. Harmful microinjecting practices among a cohort of injection drug users in Vancouver, Canada. Subst Use Misuse 2010; 45: 1351-66.
20. Mateu-Gelabert P., Gwadz M. V., Guarino H., Sandoval M., Cleland C. M., Jordan A. et al. The staying safe intervention: training people who inject drugs in strategies to avoid injection-related HCV and HIV infection. AIDS Educ Prev 2014; 26: 144-57.
21. Mackesy-Amiti M. E., Finnegan L., Ouellet L. J., Golub E. T., Hagan H., Hudson S. M. et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav 2013; 17: 2075-83.
22. Ryan R. M., Deci E. L. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol 2000; 55: 68-78.
23. Fry C. L., Lintzeris N. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). Addiction 2003; 98: 171-8.
24. Shelton B. J., Gilbert G. H., Lu Z., Bradshaw P., Chavers L. S., Howard G. Comparing longitudinal binary outcomes in an observational oral health study. Stat Med 2003; 22: 2057-70.
25. Carrieri M. P., Roux P., Cohen J., Ravaux I., Dellamonica P., Protopopescu C. et al. The impact of methadone and buprenorphine on antiretroviral-related symptoms in opioid-dependent HIV-infected individuals: results from the MANIF 2000 cohort study. 5ème Conférence Francophone VIH/SIDA, Casablanca, Morocco; 2010.
26. Carrieri M. P., Leport C., Protopopescu C., Cassuto J. P., Bouvet E., Peyramond D. et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006; 41: 477-85.
27. Montgomery S. B., Hyde J., De Rosa C. J., Rohrbach L. A., Ennett S., Harvey S. M. et al. Gender differences in HIV risk behaviors among young injectors and their social network members. Am J Drug Alcohol Abuse 2002; 28: 453-75.
28. Gollub E. L., Rey D., Obadia Y., Moatti J. P. Gender differences in risk behaviors among HIV+ persons with an IDU history. The link between partner characteristics and women's higher drug-sex risks. The Manif 2000 Study Group. Sex Transm Dis 1998; 25: 483-8.
29. Tracy D., Hahn J. A., Fuller Lewis C., Evans J., Briceno A., Morris M. D. et al. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open 2014; 4 e004988:
30. Tassiopoulos K., Bernstein J., Bernstein E. Age and sharing of needle injection equipment in a cohort of Massachusetts injection drug users: an observational study. Addict Sci Clin Pract 2013; 8: 20.
31. Le Marchand C., Evans J., Page K., Davidson P. J., Hahn J. A. Hazardous alcohol consumption among young adult IDU and its association with high risk behaviors. Drug Alcohol Depend 2013; 127: 143-9.
32. Maher L., Jalaludin B., Chant K. G., Jayasuriya R., Sladden T., Kaldor J. M. et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101: 1499-508.
33. De P., Cox J., Boivin J. F., Platt R. W., Jolly A. M. Rethinking approaches to risk reduction for injection drug users: differences in drug type affect risk for HIV and hepatitis C virus infection through drug-injecting networks. J Acquir Immune Defic Syndr 2007; 46: 355-61.
34. Gossop M., Marsden J., Stewart D., Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care 2002; 14: 77-93.
35. Colon H. M., Robles R. R., Deren S., Sahai H., Finlinson H. A., Andia J. et al. Between-city variation in frequency of injection among Puerto Rican injection drug users: East Harlem, New York, and Bayamon, Puerto Rico. J Acquir Immune Defic Syndr 2001; 27: 405-13.
36. Kral A. H., Lorvick J., Edlin B. R. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000; 24: 162-7.
37. Ebright J. R., Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002; 16: 697-712.
38. McLean S., Bruno R., Brandon S., de Graaff B. Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets. Harm Reduct J 2009; 6: 37.
39. Roux P., Carrieri M. P., Keijzer L., Dasgupta N. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Drug Alcohol Rev 2011; 30: 287-90.
40. Sacks-Davis R., Horyniak D., Grebely J., Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy 2012; 23: 176-84.
41. Tucker T., Fry C. L., Lintzeris N., Baldwin S., Ritter A., Donath S. et al. Randomized controlled trial of a brief behavioural intervention for reducing hepatitis C virus risk practices among injecting drug users. Addiction 2004; 99: 1157-66.
42. Zule W. A., Costenbader E. C., Coomes C. M., Wechsberg W. M. Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health 2009; 99: S180-6.
43. Wood R. A., Wood E., Lai C., Tyndall M. W., Montaner J. S., Kerr T. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility. Int J Drug Policy 2008; 19: 183-8.
44. Wood E., Tyndall M. W., Qui Z., Zhang R., Montaner J. S., Kerr T. Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. Am J Public Health 2006; 96: 770-3.
45. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-63; discussion 267-8.
46. Abel-Ollo K., Rahu M., Rajaleid K., Talu A., Ruutel K., Platt L. et al. Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care 2009; 21: 851-7.